FDA Launches Effort to Reshape Rare Disease Drug Development

Rare Daily Staff

The U.S. Food and Drug Administration is developing a new framework for evaluating rare disease treatments, seeking to better match its regulatory expectations to individual conditions and the evidence researchers can realistically gather from small patient populations.

The agency said the Rare Disease Framework Initiative would begin by gathering input from patients, advocates, drug developers and other stakeholders. Only about 5 percent of rare conditions have an FDA-approved treatment, according to the agency.

The effort aims to make drug development and regulatory decisions more consistent and predictable while accounting for differences among diseases, patients’ needs and the types of treatments under review. FDA officials said the changes would maintain the agency’s standards for safety and effectiveness.

“Patients and families living with rare diseases have few or no approved treatment options, and the burden of uncertainty can extend across every part of their lives,” Acting FDA Commissioner Kyle Diamantas said in the announcement.

The initiative focuses on a central challenge in rare disease drug development: determining what evidence can reasonably be generated when the population available to study is small. Rather than announcing a single new requirement for all rare disease therapies, the FDA said it would develop an approach tailored to the circumstances of each disease and treatment.

The agency’s priorities include involving patients early in development and at defined milestones, drawing more extensively on outside disease experts, and supporting new scientific methods and statistical approaches. It also plans to strengthen staff training and shared resources so that knowledge about rare disease development and review is more consistently available within the agency.

Another focus will be a risk-based approach to reviewing how therapies are made and how manufacturers control their quality, as well as to inspections conducted before approval. Those activities fall under what regulators call chemistry, manufacturing and controls, or CMC.

The FDA said it already uses regulatory flexibility and targeted programs to support rare disease treatments, but acknowledged that the limited number of conditions with approved therapies shows the need for further work.

“Patients with rare diseases and their families deserve a regulatory process that addresses the uniqueness of each of their conditions while maintaining the FDA’s rigorous standards,” said Amy Comstock Rick, director of the agency’s Rare Disease Innovation Hub, which is leading the initiative. The hub will work with the FDA’s commissioner’s office and its centers responsible for reviewing drugs and biological products.

The first public meeting will take place October 28, from 1 p.m. to 5 p.m. Eastern time, at the FDA’s White Oak campus in Silver Spring, Maryland, with participation also available through Zoom.

Additional input will come through sector-specific roundtables, formal requests for information and internal FDA feedback sessions. The agency said that process could lead to new or revised guidance, changes to regulations, staff training and organizational changes. The announcement launches development of the framework rather than putting a completed set of new regulatory requirements into effect.

Photo: Amy Comstock Rick, director of the agency’s Rare Disease Innovation Hub.